ADVENTRX Announces Upcoming Scientific Conference Presentations
March 28 2006 - 5:30AM
PR Newswire (US)
SAN DIEGO, March 28 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX) announced today that it will
present preclinical study results for its antiviral compound,
Thiovir(TM), and its oncology compound, ANX-530 (vinorelbine
emulsion) at upcoming scientific conferences: ADVENTRX will present
"Synergistic antiviral activity and additive cytotoxicity of
Thiovir combined with zidovudine" at the HIV Pathogenesis Meeting,
in Keystone, Colorado on Friday March 31 at 7:30 p.m. MST. The
poster will be presented by Shani Waninger, Ph.D., associate
director of research and development for ADVENTRX. The conference
takes place March 27 - April 2, 2006. Thiovir is a reverse
transcriptase inhibitor designed for oral delivery as a component
of highly active antiretroviral therapy (HAART) for HIV/AIDS.
Thiovir is also being developed as a drug candidate for the H5N1
influenza strain known as bird flu. ADVENTRX will present "A novel
emulsion formulation of vinorelbine attenuates venous toxicity
while maintaining antitumor efficacy" at the American Association
for Cancer Research (AACR) 97th Annual Meeting 2006 on Wednesday,
April 5 at 8:00 a.m. EST. The poster presentation will be delivered
by Mark J. Cantwell, Ph.D., vice president of research and
development. The conference takes place April 1 - 5 in Washington,
DC. ANX-530 is a new formulation of vinorelbine tartrate that
emulsifies the drug into a homogeneous suspension and is designed
to protect the venous endothelium during administration, therefore
reducing vein irritation caused by the drug. About Thiovir Thiovir
is a reverse transcriptase inhibitor designed for oral delivery as
a component of HAART for HIV/AIDS. Thiovir is a prodrug for
foscarnet that delivers both the active drug TPFA
(thiophosphonoformate) and the active metabolite PFA (foscarnet) in
an oral formulation. Thiovir is intended to deliver the benefits of
the drug foscarnet, including broad spectrum antiviral activity,
with the added benefit of oral delivery. ADVENTRX currently plans
to file an investigational new drug application (IND) with the US
Food and Drug Administration (FDA) in the first half of 2006 for a
Phase I/II clinical trial using Thiovir in HIV/AIDS. The Company is
also investigating Thiovir as a potential treatment for avian
influenza. About ANX-530 ANX-530 is a novel emulsion formulation of
vinorelbine tartrate. Vinorelbine is a chemotherapeutic agent
indicated as a single agent or in combination with cisplatin for
treatment of advanced non-small cell lung cancer (NSCLC). The
Company plans to conduct a single bioequivalency study of ANX-530
as a marketing-enabling clinical trial, a plan that was recently
affirmed by the FDA. The Company currently plans to file an IND
application in the third quarter of 2006. The proposed clinical
trial will compare the bioequivalency of ANX-530 with that of
vinorelbine in patients with advanced solid tumors. In addition,
the Company plans to collect comparative data on vein irritation
and other safety parameters as secondary endpoints. About ADVENTRX
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on introducing new technologies for
anticancer and antiviral treatments that surpass the performance
and safety of existing drugs, by addressing significant problems
such as drug metabolism, toxicity, bioavailability and resistance.
More information can be found on the Company's Web site at
http://www.adventrx.com/. Forward Looking Statement This press
release contains forward-looking statements, within the meaning of
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995, regarding ADVENTRX. Such statements are made
based on management's current expectations and beliefs. Actual
results may vary from those currently anticipated based upon a
number of factors, including uncertainties inherent in the drug
development process, the timing and success of clinical trials, the
validity of research results, and the receipt of necessary
approvals from the FDA and other regulatory agencies. For a
discussion of such risks and uncertainties, which could cause
actual results to differ from those contained in the
forward-looking statements regarding ADVENTRX, see the section
titled "Risk Factors" in ADVENTRX's last annual report on Form
10-K, as well as other reports that ADVENTRX files from time to
time with the Securities and Exchange Commission. All
forward-looking statements regarding ADVENTRX are qualified in
their entirety by this cautionary statement. ADVENTRX undertakes no
obligation to release publicly any revisions, which may be made to
reflect events or circumstances after the date hereof. DATASOURCE:
ADVENTRX Pharmaceuticals, Inc. CONTACT: Andrea Lynn of ADVENTRX
Pharmaceuticals, +1-858-552-0866 Web site: http://www.adventrx.com/
Company News On-Call:
http://www.prnewswire.com/gh/cnoc/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024